NCT04109482 Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. Status TERMINATED Phase PHASE1/PHASE2
NCT04098393 Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04093648 T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) Status WITHDRAWN Phase PHASE1
NCT04093596 Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Status COMPLETED Phase PHASE1
NCT04088890 Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Status COMPLETED Phase PHASE1
NCT04088864 CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Status COMPLETED Phase PHASE1
NCT04083183 Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases Status RECRUITING Phase PHASE1/PHASE2
NCT04083170 Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers Status TERMINATED Phase PHASE2
NCT04074746 Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Status COMPLETED Phase PHASE1/PHASE2
NCT04052334 Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Status COMPLETED Phase PHASE1
NCT04037566 CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. Status UNKNOWN Phase PHASE1
NCT04030195 Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL Status COMPLETED Phase PHASE1/PHASE2
NCT04029688 A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT04029038 Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Status WITHDRAWN Phase PHASE1/PHASE2
NCT04025216 A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers Status TERMINATED Phase PHASE1
NCT04024761 A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation Status RECRUITING Phase PHASE1
NCT04022239 Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant Status RECRUITING Phase PHASE1/PHASE2